Vagotomy, Truncal
Conditions
Keywords
truncal vagotomy, GLP-1, gastric emptying, appetite, food intake
Brief summary
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the researchers will investigate individuals with and without intact nervous supply.
Detailed description
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of intact vagal innervations on the effect of GLP-1 on the food intake, gastric emptying (GE) and appetite.
Interventions
DRUGGLP-1
1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes. After four hours an ad libitum meal will be supplied
OTHERSaline
Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes. After four hours an ad libitum meal will be supplied
Sponsors
University of Copenhagen
University Hospital, Gentofte, Copenhagen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* truncal vagotomy * normal hemoglobin * informed consent * Age, gender and weight matched controls * normal hemoglobin * informed consent
Exclusion criteria
* type 1 diabetes mellitus or type 2 diabetes mellitus * body mass index \> 30 kg/m2 * inflammatory bowel disease * intestinal resection * nephropathy (serum creatinine \> 150 µM and/or albuminuria) * liver disease (ALAT and/or ASAT \> 2 x normal value) * treatment with medicine which cannot be paused for 12 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gastric emptying | four hours | Gastric emptying will be assessed using a liquid meal with 1.5 g paracetamol added and continuous blood sampling for measuring paracetamol concentration during four hours |
| Appetite | four hours | Hunger, satiation, and fullness will be assessed before, during and after a liquid meal with 1.5 g paracetamol added using a visual analog scale (VAS) |
| Food intake | five hours | After the liquid meal test, the volunteers will be offered a meal to assessed their ad libitum food intake |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| plasma GLP-1 | four hours | — |
| endogenous GLP-1 | four hours | endogenous GLP-1 will be assessed as plasma GLP-2 concentration |
| plasma glucose | four hours | — |
| serum paracetamol | four hours | — |
| plasma GIP | four hours | — |
| serum insulin and c-peptide | four hours | — |
| plasma glucagon | four hours | — |
Countries
Denmark
Outcome results
None listed